TCTMD

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

A head-to-head comparison of paclitaxel-based DES and DCB in patients with symptomatic femoropopliteal disease, including long lesions and severe calcification, suggests that while both therapies ...
TCTMD

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

At 2 years, a next-generation, low-dose paclitaxel drug-coated balloon (DCB) continues to show good safety and efficacy compared with a standard high-dose paclitaxel DCB in the treatment of ...
Healio

Chocolate Touch DCB successful in head-to-head trial in femoropopliteal disease

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — A new study supports the safety and effectiveness of the Chocolate Touch drug-coated balloon for ...
MedPage Today

Step-Down Antiplatelet Strategy Pairs Well With DCB Angioplasty

PARIS -- Antiplatelet de-escalation worked well following drug-coated balloon (DCB) placement for acute coronary syndrome (ACS), according to the first randomized trial on this subject. In ...